176 related articles for article (PubMed ID: 31476848)
1. Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer.
Liang LJ; Hu CX; Wen YX; Geng XW; Chen T; Gu GQ; Wang L; Xia YY; Liu Y; Fei JY; Dong J; Zhao FH; Ahongjiang Y; Hui KY; Jiang XD
Cancer Res Treat; 2020 Apr; 52(2):406-418. PubMed ID: 31476848
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
4. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.
Chen H; Jiang T; Lin F; Guan H; Zheng J; Liu Q; Du B; Huang Y; Lin X
Int Immunopharmacol; 2021 Oct; 99():107929. PubMed ID: 34343940
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED
Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325
[TBL] [Abstract][Full Text] [Related]
6. Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
Zhao C; Zhang Q; Qiao W
Medicine (Baltimore); 2017 Dec; 96(50):e9276. PubMed ID: 29390380
[TBL] [Abstract][Full Text] [Related]
7. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors.
Chen JL; Pan CK; Huang YS; Tsai CY; Wang CW; Lin YL; Kuo SH; Shieh MJ
Cancer Immunol Immunother; 2021 Feb; 70(2):391-404. PubMed ID: 32761424
[TBL] [Abstract][Full Text] [Related]
9. Low- dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer.
Jiang S; Zhou Y; Zou L; Chu L; Chu X; Ni J; Li Y; Guo T; Yang X; Zhu Z
Cancer Med; 2023 Feb; 12(4):4434-4445. PubMed ID: 36065943
[TBL] [Abstract][Full Text] [Related]
10. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
11. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
Yang Y; Wang C; Sun H; Jiang Z; Zhang Y; Pan Z
Cancer Gene Ther; 2021 Feb; 28(1-2):89-97. PubMed ID: 32533100
[TBL] [Abstract][Full Text] [Related]
12. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
13. Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model.
Basler L; Kowalczyk A; Heidenreich R; Fotin-Mleczek M; Tsitsekidis S; Zips D; Eckert F; Huber SM
Cancer Immunol Immunother; 2018 Apr; 67(4):653-662. PubMed ID: 29335856
[TBL] [Abstract][Full Text] [Related]
14. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.
Wang H; Gao C; Li X; Chen F; Li G
Sci Rep; 2024 Mar; 14(1):7140. PubMed ID: 38532022
[TBL] [Abstract][Full Text] [Related]
15. Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report.
Yan H; Li X; Peng Y; Zhang P; Zou N; Liu X
Medicine (Baltimore); 2020 Oct; 99(43):e22925. PubMed ID: 33120847
[TBL] [Abstract][Full Text] [Related]
16. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
18. Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.
Zhao J; Zhang X; Gong C; Zhang J
Medicine (Baltimore); 2017 Dec; 96(50):e9259. PubMed ID: 29390367
[TBL] [Abstract][Full Text] [Related]
19. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials.
Liang L; Wen Y; Hu R; Wang L; Xia Y; Hu C; Qiao Y; Geng X; Chen T; Fei J; Hui K; Jiang X
Cancer Immunol Immunother; 2019 Sep; 68(9):1467-1477. PubMed ID: 31451841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
